NERLYNX® (neratinib, oral)
HER2-positive early-stage breast cancer (extended adjuvant)
ApprovedCommercial
Key Facts
Indication
HER2-positive early-stage breast cancer (extended adjuvant)
Phase
Approved
Status
Commercial
Company
About Puma Biotechnology
Puma Biotechnology is a publicly traded biopharmaceutical company dedicated to enhancing cancer care through innovative therapeutics. The company successfully commercialized NERLYNX® (neratinib) for extended adjuvant treatment of HER2-positive early-stage breast cancer and is now expanding its pipeline via in-licensing, most notably with alisertib. Its strategic direction involves lifecycle management for its commercial asset while advancing mid-stage clinical programs in high-need oncology indications, positioning it for potential future growth.
View full company profile